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ventilated with a median SOFA score = 6. The median cumulated time dedicated to 
one patient by physicians, nurses and caregivers was 10h20 over the 24-hour period 
(1h15 by physician, 6h08 by nurses and 2h57 by caregivers). CONCLUSIONS: The 
median time of more than 10 hours directly dedicated to a patient is a key information 
for the estimation of the real cost of one day stay in ICU
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OBJECTIVES: This study aims to identify how medication compliance and/or persis-
tence were assessed in the cost-effectiveness analysis, and what the impact was on 
ICER(Incremental cost-effectiveness ratio). METHODS: Pharmacoeconomic studies 
with compliance and/or persistence measures, had published from March 2005 to 
February 2010, were searched through MEDLINE. Articles were included if they 
integrated medication compliance and/or persistence into the economic analysis 
model. We reviewed the target diseases, the model designs, and the impact of non-
compliance on the treatment costs and effects. After that, the results were compared 
with a previous review article of ISPOR MCP(Medication compliance and persistence 
special interest group) had conducted in 2007. RESULTS: The search identiﬁ ed 77 
articles, and 10 of them were selected. Even though the overall kinds of target diseases 
were different, most of them were chronic diseases, which have remission and relapse 
as common characteristics. Variety of modeling techniques such as decision-analysis 
and Markov model, DES (Discrete event simulation) were used for the evaluations. 
In decision-analysis models, the branches of decision trees represented different level 
of compliance. In case of Markov models, transition probabilities assumed to be higher 
for those patients who were non-persistent or non-adherent to treatment. Finally, 
considering the effect of compliance and/or persistence, it may cause decrease of ICER 
for new intervention. CONCLUSIONS: We found that incorporating compliance and/
or persistence into economic evaluations lead to favorable results to new intervention. 
However, there was a lack of methodological rigor and consistency in deﬁ nition. 
Therefore, development of guidance is needed for measurement, analysis, interpreta-
tion, and application of compliance and persistence from variety of data sources.
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BACKGROUND: Discounting health effects remains a matter of great debate these 
days. Currently, discussion focuses on whether health effects should be discounted at 
the same rate as costs or not. High discount rates for health effects are impacting 
negatively on the cost-effectiveness of screening and vaccination programs. Discount-
ing health at a lower rate than wealth has however been argued to result in theoretical 
inconsistencies and practical unnecessary delays in implementation of health pro-
grams. Many authors have therefore assumed that there is a one-to-one relationship 
between health and wealth. OBJECTIVES: We investigate the rationality of several 
assumptions involved towards current discounting procedures. We especially investi-
gated the assumption of a one-to-one relationship between health and wealth. 
METHODS: We performed a literature review to link the issues in current methods 
of discounting health effects with the assumptions involved. Furthermore, we analyzed 
other possible linkages of health rather than with wealth only. RESULTS: We noticed 
that although income might depict the marginal substitution between all commodities, 
it seems that externalities are not accounted for. Yet, research has shown that all forms 
of economic growth exert intrinsically negative population health effects among the 
communities that are most directly involved in the transformations which it entails. 
This may obviously impact on valuation of health states and preferences, measured 
using instruments as the EuroQol-5D. These arguments support differential discount-
ing of health effects, and potential further extensions such as differential discounting 
of life and quality. CONCLUSIONS: Although there might be a relationship between 
wealth and health, it appears that externalities may play an additional role on the 
quality of life. Therefore, it seems that we should regard the discounting problem of 
health effects as an interlinked system, rather than an equation with only health and 
wealth and allow differential discounting of, and potentially even within, health 
effects.
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Three of the more common methods of estimating the optimal price for prospective 
pharmaceutical products are willingness-to-pay, value-based price appraisal, and refer-
ence price benchmarking assessments. Each method in itself, however, has inherent 
limitations. The objective of this study is to present a novel technique in pharamceuti-
cal price estimation for arriving at an evidence based price-point. Willingness-to-pay, 
as assessed through primary research, is limited by lack of knowledge of product prices 
and the disconnect between respondent answers and real-life price acceptance. Value-
based price appraisals, utilizing cost-of-treatment models to estimate the price at which 
new products are cost-effective relative to other options, are subject to error and 
interpretation and are rarely taken at face value by stakeholders who drive price 
acceptance. Reference price benchmarking, looking to market analogues to gauge 
appropriate price-points for new products, can be a good starting point but does not 
take into account unique product differences, perceived or real, of new products. To 
address gaps and weaknesses of any given individual method, our method of determin-
ing optimal product price uses all three pricing methodologies to triangulate on a 
recommended price-point. Market analogues are used as a base-price starting point. 
a value-based cost-of-treatment model is used to determine potential cost-savings that 
can be offset in price. Finally, primary research is used to determine how to modify 
that price based on perceived differences in the target product, and the how cost-
savings might be considered in price. 
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
Management Methods
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OBJECTIVES: Primary care patient data are increasingly used for research and record-
ing of death is important as it helps deﬁ ne end of follow-up and mortality may be a 
study outcome. This study compared recording of death in a UK primary care database 
with national death rates for England, Wales, Scotland and Northern Ireland (NI). 
METHODS: The annual number of deaths (1990 to 2008) for each country was 
collected after the mortality recording quality threshold from The Health Improvement 
Network (THIN) database. THIN holds longitudinal anonymised primary care 
medical records from an increasing number of practices over time and currently 
contains data from more than 450 practices throughout the UK. Annual age and 
gender speciﬁ c person time was estimated and multiplied with annual age, gender and 
country speciﬁ c death rates to derive the expected number of deaths. Observed deaths 
divided by expected deaths provided the standardised mortality ratio (SMR) and 
Byar’s approximation formula was applied to derive 95% conﬁ dence intervals (CI). 
An SMR close to 1.0 indicates that recorded deaths are near national rates. RESULTS: 
The average annual number of practices was 263.5 (standard deviation (SD):80.2) for 
England, 18.8 (SD:8.5) for Wales, 33.6 (SD:17.0) for Scotland, and 14.0 (SD:7.6) for 
NI. Average annual death rate per 1,000 population in THIN was 10.41 (SD:1.05) 
overall, 10.38 (SD:1.02) in England, 11.25 (SD:1.45) in Wales, 11.03 (SD:1.54) in 
Scotland and 8.29 (SD:0.77) in NI. The average annual SMR was 0.88 (SD:0.02) 
overall, 0.88 (SD:0.02) in England, 0.94 (SD:0.05) in Wales, 0.94 (SD:0.10) in Scot-
land and 0.91(SD:0.07) in NI. CONCLUSIONS: The observed death rates were 
slightly lower than expected (SMR < 1) over time and in each country, especially in 
England. Social deprivation impacts death rates and as unadjusted for this could 
explain some variation. Reasons for lower rates need to be investigated further.
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OBJECTIVES: The objective of the study is to obtain behaviour of the cost’s relative 
average weights of the assistance with the retrospective application of the Adjusted 
Clinical Groups (ACG’s) in 16 teams of Primary Care with an attended population in 
the clinical practice use. METHODS: Multicentre, retrospective study based on elec-
tronic records of patients seeking care during 2008 in the regions of Aragon, Balears 
and Catalonia. Main measurements: universal variables (age, sex, health service-family 
practice/paediatrics) and dependent variables: episodes and total cost (visits, diagnostic 
test, referrals, drugs). The ACG case-mix System software (version 8.2; N = 106) 
classiﬁ ed subjects into a single category for a given annual resource consumption. The 
model of cost per each patient was established differencing the ﬁ x cost and the vari-
able. Outlier patients were considered those surpassing T = Q3 + 1.5(Q3-Q1) = 
c1778.6 for total cost expenditure. Log transformation of the dependent variable was 
carried out to reduce skewness of the distribution and make it close to normal. 
Explanatory power was calculated by coefﬁ cients of determination (R2). Statistical 
software: SPSS, P < 0.05. RESULTS: The total number of the studied patients was 
227,235 (intensity of use: 75.6%), with an average 4.5 ± 3.2 episodes. The age average 
was of 44.1 ± 23.7 years, 56.6% women (13.5% paediatrics). The distribution of 
costs was c148,657,137. The total unitary cost per patient/year c654.2 ± 851.7 (rela-
tive weights of reference). Patient’s case-mix: 57.2% of the study population was 
grouped into 10 ACG. The explanatory power of the ACG classiﬁ cation system was 
36.3% (Ln: 41.2%), P < 0,001. a total of 6.2% of patients were considered Outliers 
(N = 14.066). CONCLUSIONS: The ACG are an acceptable system of classiﬁ cation 
of patients in situation of clinical practice use. Some ACG classiﬁ cation categories 
should be separeted due to the high outliers number.
